Ronnie Fass

List of Publications by Year
in descending order

32 papers	1,120 citations	623734 14 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	772 citing authors

#	Article	IF	Citations
1	The relationship between gastroesophageal reflux disease and autism spectrum disorder in adult patients in the United States. Neurogastroenterology and Motility, 2022, 34, e14295.	3.0	4
2	Development of quality indicators for the diagnosis and management of achalasia. Neurogastroenterology and Motility, 2021, 33, e14118.	3.0	9
3	Alteration in Integrated Relaxation Pressure During Successive Swallows in Subjects With Normal Manometry Versus Those With Esophagogastric Junction Outflow Obstruction. Journal of Neurogastroenterology and Motility, 2021, 27, 185-190.	2.4	1
4	Esophagogastric junction outflow obstruction. Neurogastroenterology and Motility, 2021, 33, e14193.	3.0	35
5	Endoscopic Anti-Reflux Procedures: Ready for Clinical Use?. Current Treatment Options in Gastroenterology, 2021, 19, 399-420.	0.8	3
6	No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies. Alimentary Pharmacology and Therapeutics, 2021, 54, 606-615.	3.7	5
7	Sorting out the Relationship between Gastroesophageal Reflux Disease and Sleep. Current Gastroenterology Reports, 2021, 23, 15.	2.5	11
8	Esophageal motility disorders on highâ€resolution manometry: Chicago classification version 4.0^{Â©}. Neurogastroenterology and Motility, 2021, 33, e14058.	3.0	468
9	ESNM/ANMS consensus paper: Diagnosis and management of refractory gastroâ€esophageal reflux disease. Neurogastroenterology and Motility, 2021, 33, e14075.	3.0	68
10	Barrettâ€™s esophagus patients are becoming younger: analysis of a large United States dataset. Esophagus, 2020, 17, 190-196.	1.9	5
11	Durability of Esophageal Motor Disorders Identified on High-Resolution Esophageal Manometry: A Case Series. Advances in Therapy, 2020, 37, 2560-2571.	2.9	3
12	Protonâ€pump inhibitor use and the development of new ischemic heart disease in nonâ€cardiac chest pain patients. Neurogastroenterology and Motility, 2020, 32, e13844.	3.0	3
13	The Risk of Acute Myocardial Infarction in Patients With Gastroesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2020, 26, 471-476.	2.4	11
14	The effect of sleep deficiency on esophageal acid exposure of healthy controls and patients with gastroesophageal reflux disease. Neurogastroenterology and Motility, 2019, 31, e13705.	3.0	21
15	Management of Gastroesophageal Reflux Disease in the Elderly Patient. Drugs and Aging, 2019, 36, 1073-1081.	2.7	9
16	Overlap Between GERD and Functional Esophageal Disordersâ€”a Pivotal Mechanism for Treatment Failure. Current Treatment Options in Gastroenterology, 2019, 17, 161-164.	0.8	10
17	High resolution vs conventional esophageal manometry in the assessment of esophageal motor disorders in patients with nonâ€cardiac chest pain. Neurogastroenterology and Motility, 2018, 30, e13282.	3.0	7
18	Severity of ineffective esophageal motility is associated with utilization of skeletal muscle relaxant medications. Neurogastroenterology and Motility, 2018, 30, e13235.	3.0	8

#	Article	IF	Citations
19	Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 4865-4882.	2.4	138
20	Editorial: management of eosinophilic oesophagitis â€“ efficacy vs. effectiveness. Alimentary Pharmacology and Therapeutics, 2016, 44, 198-199.	3.7	1
21	Utilisation of surgical fundoplication for patients with gastroâ€oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013. Alimentary Pharmacology and Therapeutics, 2016, 43, 1124-1131.	3.7	42
22	Review article: the current treatment of nonâ€cardiac chest pain. Alimentary Pharmacology and Therapeutics, 2016, 43, 213-239.	3.7	44
23	Letter: oesophageal eosinophilia must be excluded before determining prevalence of eosinophilic oesophagitis - authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2015, 42, 629-629.	3.7	0
24	Letter: is there a relationship between Barrett's oesophagus length and body mass index? Authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 702-703.	3.7	0
25	Unmet Needs in the Treatment of Gastroesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2015, 21, 309-319.	2.4	44
26	The effect of antireflux treatment on the frequency of awakenings from sleep in patients with Gastroesophageal reflux disease. Neurogastroenterology and Motility, 2015, 27, 237-245.	3.0	15
27	The relationship between length of Barrett's oesophagus mucosa and body mass index. Alimentary Pharmacology and Therapeutics, 2015, 41, 137-144.	3.7	17
28	The 2011â€“2014 prevalence of eosinophilic oesophagitis in the elderly amongst 10 million patients in the United States. Alimentary Pharmacology and Therapeutics, 2015, 41, 1016-1022.	3.7	51
29	Naps Are Associated More Commonly With Gastroesophageal Reflux, Compared With Nocturnal Sleep. Clinical Gastroenterology and Hepatology, 2015, 13, 94-99.	4.4	17
30	The role of pain modulators in esophageal disorders â€“ no pain no gain. Neurogastroenterology and Motility, 2014, 26, 603-610.	3.0	48
31	Commentary: the proton pump inhibitor test â€“ does it have a role in eosinophilic oesophagitis?. Alimentary Pharmacology and Therapeutics, 2014, 39, 896-897.	3.7	1
32	Treatment of Esophageal Motility Disorders Based on the Chicago Classification. Current Treatment Options in Gastroenterology, 2014, 12, 441-455.	0.8	21